SCHEMBL2920288

SCHEMBL2920288

Cc1cc(Nc2ncc3ccc(N)c(C)c3n2)cc2[nH]ncc12

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 7/20 0.37
PDGFRA P16234 7/20 0.37
SYK P43405 6/20 0.37
LYN P07948 2/20 0.37
TXK P42681 2/20 0.37
BTK Q06187 2/20 0.37
CDC7 O00311 1/20 0.37
IGF1R P08069 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
GRM4 Q14833 1/20 0.35
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCND1 P24385 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2919211 0.87 CDC7 (0.41) PDGFRBPDGFRASYKLYNTXK
SCHEMBL2916270 0.87 CDK4 (0.41) PDGFRBPDGFRASYKLYNTXK
SCHEMBL2910896 0.85 CDC7 (0.52) PDGFRBPDGFRASYKCDC7IGF1R
SCHEMBL2912557 0.85 IGF1R (0.45) PDGFRBPDGFRAIGF1RCDK1CDK4
SCHEMBL13175217 0.84 PDGFRB (0.36) PDGFRBPDGFRASYKLYNTXK
SCHEMBL2917081 0.83 SYK (0.41) PDGFRBPDGFRASYKLYNTXK
SCHEMBL2919558 0.83 CDC7 (0.40) PDGFRBPDGFRASYKLYNTXK
SCHEMBL2919831 0.81 IGF1R (0.43) PDGFRBPDGFRASYKIGF1RCDK1
SCHEMBL2917456 0.81 CDK2 (0.35) PDGFRBPDGFRACDC7KDM4EALDH1A1
SCHEMBL2919933 0.80 VRK1 (0.38) PDGFRBPDGFRASYKCDC7KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed
WO-2009084695-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K PDGFRB 1018/4885PDGFRA 862/4885SYK 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.